Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Bioorg Chem ; 85: 168-178, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30616098

RESUMEN

Despite the increasing need of new antituberculosis drugs, the number of agents approved for the market has fallen to an all-time low. In response to the emerging drug resistance followed, structurally unique chemical entities will be highlighted. decaprenylphosphoryl-ß-d-ribose oxidase (DprE1) participating in the biosynthesis of mycobacterium cell wall is a highly vulnerable and validated antituberculosis target. On the basis of it, a systematic strategy was applied to identify a high-quality lead compound (compound 50) that inhibits the essential enzyme DprE1, thus blocking the synthesis of the mycobacterial cell wall to kill M. tuberculosis in vitro and in vivo. Correspondingly, the rational design and synthetic strategy for compound 50 was reported. Notably, the compound 50 has been confirmed to be no toxicity. Altogether, our data suggest the compound 50 targeting DprE1 is a promising candidate for the tuberculosis (TB) therapy.


Asunto(s)
Oxidorreductasas de Alcohol/antagonistas & inhibidores , Antituberculosos/uso terapéutico , Proteínas Bacterianas/antagonistas & inhibidores , Barbitúricos/uso terapéutico , Tuberculosis/tratamiento farmacológico , Animales , Antituberculosos/síntesis química , Antituberculosos/toxicidad , Barbitúricos/síntesis química , Barbitúricos/toxicidad , Chlorocebus aethiops , Bases de Datos de Compuestos Químicos , Evaluación Preclínica de Medicamentos , Femenino , Ligandos , Masculino , Ratones Endogámicos C57BL , Pruebas de Sensibilidad Microbiana , Simulación del Acoplamiento Molecular , Mycobacterium smegmatis/efectos de los fármacos , Mycobacterium tuberculosis/efectos de los fármacos , Bibliotecas de Moléculas Pequeñas/síntesis química , Bibliotecas de Moléculas Pequeñas/uso terapéutico , Bibliotecas de Moléculas Pequeñas/toxicidad , Tuberculosis/patología , Células Vero
2.
Drug Test Anal ; 3(6): 337-44, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21698778

RESUMEN

Studies in the field of forensic pharmacology and toxicology would not be complete without some knowledge of the history of drug discovery, the various personalities involved, and the events leading to the development and introduction of new therapeutic agents. The first medicinal drugs came from natural sources and existed in the form of herbs, plants, roots, vines and fungi. Until the mid-nineteenth century nature's pharmaceuticals were all that were available to relieve man's pain and suffering. The first synthetic drug, chloral hydrate, was discovered in 1869 and introduced as a sedative-hypnotic; it is still available today in some countries. The first pharmaceutical companies were spin-offs from the textiles and synthetic dye industry and owe much to the rich source of organic chemicals derived from the distillation of coal (coal-tar). The first analgesics and antipyretics, exemplified by phenacetin and acetanilide, were simple chemical derivatives of aniline and p-nitrophenol, both of which were byproducts from coal-tar. An extract from the bark of the white willow tree had been used for centuries to treat various fevers and inflammation. The active principle in white willow, salicin or salicylic acid, had a bitter taste and irritated the gastric mucosa, but a simple chemical modification was much more palatable. This was acetylsalicylic acid, better known as Aspirin®, the first blockbuster drug. At the start of the twentieth century, the first of the barbiturate family of drugs entered the pharmacopoeia and the rest, as they say, is history.


Asunto(s)
Química Farmacéutica/historia , Descubrimiento de Drogas/historia , Alcaloides/análisis , Alcaloides/historia , Alcaloides/aislamiento & purificación , Analgésicos/síntesis química , Analgésicos/historia , Analgésicos/uso terapéutico , Antipiréticos/síntesis química , Antipiréticos/historia , Antipiréticos/uso terapéutico , Aspirina/síntesis química , Aspirina/historia , Aspirina/uso terapéutico , Barbitúricos/síntesis química , Barbitúricos/historia , Barbitúricos/uso terapéutico , Química Orgánica/historia , Hidrato de Cloral/síntesis química , Hidrato de Cloral/historia , Hidrato de Cloral/uso terapéutico , Cloroformo/síntesis química , Cloroformo/historia , Cloroformo/uso terapéutico , Industria Farmacéutica/historia , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Historia Antigua , Humanos , Preparaciones Farmacéuticas/síntesis química , Preparaciones Farmacéuticas/historia , Farmacología/historia , Preparaciones de Plantas/química , Preparaciones de Plantas/historia , Preparaciones de Plantas/aislamiento & purificación , Preparaciones de Plantas/uso terapéutico , Toxicología/historia
3.
Arch Pharm (Weinheim) ; 342(8): 462-8, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19565603

RESUMEN

A series of 1-(6-substituted-1,3-benzothiazol-2-yl)-3-(substituted phenyl)hexahydro-2,4,6-pyrimidinetriones 4a-t were synthesized starting from substituted anilines. These compounds contained two active anticonvulsant pharmacophores, benzothiazole and barbituric acid. Structures of the compounds were confirmed on the basis of different spectroscopic techniques. All the compounds were evaluated for their anticonvulsant activity. Three compounds 4c, 4d, and 4s showed promising anticonvulsant activities in Maximal Electroshock Seizure test (MES) and subcutaneous pentylenetetrazole test (scPTZ). They also displayed a wide safety profile when tested for the minimal motor impairment test.


Asunto(s)
Compuestos de Anilina/síntesis química , Compuestos de Anilina/uso terapéutico , Anticonvulsivantes/síntesis química , Anticonvulsivantes/uso terapéutico , Barbitúricos/síntesis química , Barbitúricos/uso terapéutico , Benzotiazoles/síntesis química , Benzotiazoles/uso terapéutico , Convulsiones/tratamiento farmacológico , Animales , Sitios de Unión , Evaluación Preclínica de Medicamentos , Electrochoque , Ratones , Actividad Motora/efectos de los fármacos , Pentilenotetrazol , Convulsiones/inducido químicamente , Relación Estructura-Actividad
4.
Eur J Med Chem ; 41(10): 1223-9, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16919852

RESUMEN

A series of 5-[(N-substituted benzylidenylimino)amino]-2-oxo/thiobarbituric acids (3a-3h) have been synthesized by the condensation of 5-hydrazino-2-oxo/thiobarbituric acids (2a-2b) with various aromatic aldehydes. Cycloaddition of thioglycolic acid to 3a-3h, yielded 5-[(2'-substituted phenyl-4'-oxothiazolidin-3'-yl)amino]-2-oxo/thiobarbituric acids (4a-4h). All these compounds were screened, in vivo, for their anticonvulsant activity and acute toxicity studies. Compounds 4f and 4g were found to be most potent compounds of this series and were compared with the reference drugs, phenytoin sodium, lamotrigine and sodium valproate. The structures of these compounds have been established by IR, 1H NMR and mass spectroscopic data.


Asunto(s)
Anticonvulsivantes/síntesis química , Anticonvulsivantes/farmacología , Barbitúricos/síntesis química , Barbitúricos/farmacología , Tiazolidinas/síntesis química , Tiazolidinas/farmacología , Animales , Anticonvulsivantes/toxicidad , Barbitúricos/toxicidad , Ciclización , Evaluación Preclínica de Medicamentos , Espectroscopía de Resonancia Magnética , Espectrometría de Masas , Ratones , Estructura Molecular , Convulsiones/tratamiento farmacológico , Sensibilidad y Especificidad , Estereoisomerismo , Tiazolidinas/toxicidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA